Regulatory Archives - Page 29 of 40

Director/PDMR Shareholding

18.9.2018

RNS Number : 0993B

Faron Pharmaceuticals Oy

18 September 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

Person Closely Associated with PDMR Dealing

TURKU – FINLAND, 18 September 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 17 September 2018 it was notified of the following person closely associated with PDMR dealing.

On 17 September 2018, a person closely associated with Dr. Matti Karvonen, Chief Medical Officer of Faron, had acquired 4,414 ordinary shares in Faron at a price of 100 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (“MAR”).

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Minja Pfeiffer
2	Reason for notification
a.	Position/Status	A person closely associated with the Chief Medical Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			100 pence	4,414

d.	Aggregated information – Aggregated Volume – Price	N/A N/A
e.	Date of the transaction	September 17, 2018
f.	Place of the transaction	London Stock Exchange, AIM Market

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials and in 2017 received advice from US FDA to proceed directly to BLA submission following completion of EU and Japanese Phase III studies. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Turn-on-your-Immunity or Turn-It may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.

END

DSHFKFDBFBKKBCD

Faron announces CTA filing for Clevegen

17.9.2018

Faron Pharmaceuticals Ltd

(“Faron” or the “Company”)

Faron Announces Filing of Clinical Trial Application for precision cancer immunotherapy Clevegen

TURKU – FINLAND, 17 September 2018 – Faron Pharmaceuticals Ltd (“Faron”) (AIM: FARN), the clinical stage biopharmaceutical company, today announces that it has filed a Clinical Trial Application (CTA) for Clevegen, its wholly-owned novel precision cancer immunotherapy drug, in development for the treatment of selected metastatic or inoperable tumours.

Clevegen is a novel anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages. Clever-1, a cell surface receptor expressed mainly by tumour vascular endothelial cells and monocytes/macrophages, has been shown to control tumour growth (Karikoski et al., 2014), cell-mediated immunity (Palani et al. 2016) and to participate in the control of B cell response and humoral antibody production (Dunkel et al. 2018).

Today’s CTA filing is a key step towards initation of Faron’s MATINS study, a first-in-human open label Phase I/II adaptive design clinical trial to investigate the safety and efficacy of Clevegen in selected metastatic or inoperable solid tumours. The selected tumours under investigation are cutaneous melanoma, hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancer.

The first part of the trial deals with safety and dose escalation to optimize the dosing. The cohort expansion parts II and III will recruit only patients who show increased number of Clever-1 positive circulating monocytes, making the treatment precisely targeted and maximizing the chances of success for efficacy. The treatment, if successful, may ultimately be used as a stand alone therapy or in combination with other immunotherapies like PD-1 inhibitors.

The Company plans to conduct the MATINS trial’s dose escalation part in Finland, UK and Netherlands with four to five sites, and increase site numbers during the cohort expansion stage. Patient recruitement for the study is expected to begin in Q4 2018.

Dr Petri Bono, the Principle Investigator of the MATINS trial, said: “I look forward to initiating the MATINS trial patient recruitment since a truly novel approach to break the tumour immune suppression is used in this phaseI/II study. I strongly believe that new immunosuppression releasing approaches (such as anti-Clever-1 antibody) have the potential to become the next wave of cancer treatments”

Dr Markku Jalkanen, CEO of Faron, said: “We are making rapid progress with our Clevegen programme and this CTA filing is an important milestone. This precision therapy for cancers with very few treatment options has a unique mechanism of action which, coupled with promising pre-clinical data and human ex-vivo data, already indicates the product’s potential in a broad range of indications. We look forward to beginning patient recruitment later this year and moving Clevegen into the clinic.”

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker

Emma Earl, Freddy CrossleyPhone: +44 207 886 2500

About Clevegen®

Clevegen is based on Faron’s turn-on-your-immunity technology platform. Potential indications include immuno-oncology, chronic infections and vaccination enhancement, which all involve the presence of these same macrophages as immune suppressive cell type.

In the context of cancer Clevegen, by binding Clever-1, prevents Tumor Associated Macrophage (TAM) infiltration into a tumour and blocks TAM-to-Tumour cell interaction triggering TAM transformation of tumour supportive cell types. It therefore reduces tumour associated suppression of the human immune system and converts the whole immune environment around a tumour to immune stimulating allowing a patient’s own immune system to combat cancer, known as “immunotherapy”. Clevegen elicts a local tumour effect which similar to the cell-mediated immune response against infections in normal tissues. This kind of removal of immune suppression locally limits risk of autoimmune reaction, a potentially severe side effect observed with some immune checkpoint inhibitors. The Directors of Faron believe that Clevegen is well differentiated from competing products as it specifically targets tumour promoting anti-inflammatory M2 TAMs and converts them into M1 TAMs while leaving intact the existing M1 TAMs. This unique mode of action of Clevegen induces immune activation against tumours. Clever-1 blocking results especially in activation of Th1 mediated immunity. The involvement of these Clever-1 positive myeloid cells in tumour progression can be verified from a simple blood sample analysis (liquid biopsy) making the treatment precise.

About MATINS study

MATINS study is a first-in-human open label adaptive design Phase I/II adaptive clinical trial in selected metastatic or inoperable solid tumours to investigate the safety and efficacy of Clevegen. The selected tumours are cutaneous melanoma, hepatobiliary, pancreatic, ovarian and colorectal cancer, which are all known to contain high amounts of Clever-1 positive tumour associated macrophages (TAMs). The trial is to be run in three parts. Part I will be conducted to determine the safe and tolerable dose of Clevegen, which will then be used in Part II to expand the cohorts of individual tumour types. Part III of the trial aims to confirm the efficacy of Clevegen with the cohorts selected based on Part II. The principle Investigator for the trial is Dr. Petri Bono from the Helsinki University Hospital, who has participated in several firat-in-man clinical trials in the area of immune oncology and is also a member of ESMO (European Society of Clinical Oncolgy) GU cancer Scientific Advisory Board.

About Faron Pharmaceuticals Ltd

New data published on Clever-1 function

12.9.2018

Faron Pharmaceuticals Ltd

(“Faron” or the “Company”)

Clever-1 participates in the control of humoral (antibody-mediated) immunity

– New data published by Frontiers in Immunology

TURKU – FINLAND, 12 September 2018 – Faron Pharmaceuticals Ltd (“Faron”) (AIM: FARN), the clinical stage biopharmaceutical company, announces today new data on Clever-1 function in the control of antibody production by B-lymphocytes (B cells).

Clever-1, a cell surface receptor expressed mainly by endothelial cells and monocytes/macrophages, has previously been shown to control cell-mediated immunity (Palani et al. 2016). The recent work by Dunkel and colleagues, published online by Frontiers in Immunology, shows for the first time that Clever-1 also participates in the control of B cell response and humoral antibody production. The data suggest that Clever-1 serves as an endogenous immunosuppressive molecule in monocytes/macrophages, where it maintains the production of inflammatory cytokines at physiological levels. When Clever-1 is removed from monocytes/macrophages, one consequence of the unrestrained production of inflammatory cytokines is the increased antibody production by B cells.

Deleting or neutralizing Clever-1 has previously been reported to augment antitumor immune responses in melanoma, lymphoma and breast cancer. The efficacy of anti-Clever-1 antibodies in these experimental models supports Faron’s development of Clevegen, its fully human anti-Clever-1 antibody, under investigation as a potential cancer immunotherapy and due to enter the clinic later this year.

The observations by Dunkel et al suggest that disrupting the function of Clever-1 should not lead to the suppression of antibody production but, rather, could improve humoral immune responses against tumor antigens and during vaccinations.

Commenting on this finding, Dr Markku Jalkanen, CEO of Faron, said: “This is a fascinating finding and builds up further evidence for the importance to control Clever-1 function in conditions where active immune suppression can cause disease or worsen disease development. It provides further scientific rationale for our Vaccination Response Enhancement Technology (VRET) programme, which is currently under early investigation with Clevegen.”

Referred article: Dunkel J, Viitala M, Karikoski M, Rantakari P, Virtakoivu R, Hollmén M, Jalkanen S and Salmi M. Macrophage Clever-1 regulates antibody production. Frontiers in Immunolgy. On line code Front. Immunol. | doi: 10.3389/fimmu.2018.02257

https://www.frontiersin.org/articles/10.3389/fimmu.2018.02257/abstract

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Matthew Neal, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

Holding(s) in Company

9.7.2018

RNS Number : 9946T

Faron Pharmaceuticals Oy

09 July 2018

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			Faron Pharmaceuticals Oy
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ:
3. Details of person subject to the notification obligation^iv
Name			Tom-Erik Lind
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)^v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached^vi:			05.07.2018
6. Date on which issuer notified (DD/MM/YYYY):			06.07.2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached	9,07 %			9,07 %	31,027,894
Position of previous notification (if applicable)	8,23 %			8,23 %

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
FI4000153309		2,813,835					9,07 %


SUBTOTAL 8. A		2,813,835					9,07 %

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii				X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv (please add additional rows as necessary)
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold






10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information^xvi

Place of completion	Tampere
Date of completion	09/07/2018

END

HOLFMGGNNLKGRZG

Clevegen successful toxicity studies

28.6.2018

Faron Pharmaceuticals Ltd

(“Faron” or the “Company”)

Clevegen shows good safety and potential to block Clever-1 on circulating monocytes

· Wholly-owned Clevegen (FP-1305) shows no toxicity in dose escalation studies in large preclinical models

· The no-observed-adverse-effect-level (NOAEL) was 100 mg/kg, which is roughly 30 times higher concentration than needed for Clever-1 occupancy in vivo

· Clevegen also blocked Clever-1 on circulating monocytes as expected. The duration of blocking was dose dependent and resumed to normal level in 20 days in the highest dose

· The Company expects CTA filing for MATINS study in Q3 2018 and first patient recruitment in Q4 2018

TURKU – FINLAND, 28 June 2018 – Faron Pharmaceuticals Ltd (“Faron”) (AIM: FARN), the clinical stage biopharmaceutical company, today announces successful toxicity studies and control of blood Clever-1 positive monocytes, precursor cells to tumour associated macrophages (TAM) in large preclinical models.

The toxicity studies were designed to fulfil regulatory requirements for 3-week interval intravenous administration of Clevegen, typical for other anti-cancer antibodies currently in use. FP-1305 is a humanized IgG4 monoclonal antibody produced in CHO -cells by Faron collaborator Abzena. The FP-1305 drug product in its final formulation was administered as a single dose at 3, 30 and 100 mg/kg.

No toxicologically relevant changes were observed in any subject. No major changes were observed after treatment with FP-1305 in T lymphocytes subsets. The binding of Clevegen to its receptor on circulating CD14+ monocytes was confirmed by investigating the receptor occupancy, the recovery of which occurred between 3 to 20 days after dosing in a dose-dependent manner. No relevant changes were present in cytokines and no anti-drug antibodies (ADA) were detected in any subject. Therefore, the highest dose of 100 mg/kg was considered the no-observed-adverse-effect-level (NOAEL).

Dr Markku Jalkanen, CEO of Faron, said: “We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen and the high NOAEL concentration. We were also delighted to learn that Clevegen administration blocks Clever-1 on circulating monocytes, which are one group of our target cells in our MATINS Phase I/II clinical trial. Our plan is now to file the MATINS clinical trial application (CTA) during Q3 2018 and, as previously announced, initiate this first Clevegen human trial in Q4 2018.”

About MATINS trial: MATINS study is first-in-human open label Phase I/II adaptive clinical trial in selected metastatic or inoperable solid tumours to investigate the safety and efficacy of Clevegen (FP-1305). The selected tumours are cutaneous melanoma, hepatobiliary, pancreatic, ovarian or colorectal cancer, which are all known to contain high amounts of Clever-1 positive TAMs. The trial is to be run in three parts. Part I will be conducted to determine the safe and tolerable dose of Clevegen, which will then be used in Part II to expand the cohorts of individual tumour types. Part III of the trial aims to confirm the efficacy of Clevegen with the cohorts selected based on Part II.

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker

Freddy Crossley, Emma Earl, Ryan McCarthy

Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

Holdings in Company

22.6.2018

TR-1: Standard form for notification of major holdings


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			Faron Pharmaceuticals Oy 7437009H31TO1DC0EB42
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ: Disclosure as per company’s Articles of Association						X
3. Details of person subject to the notification obligation^iv
Name			Legal & General Group Plc (Group) Legal & General Investment Management Limited (LGIM) Legal & General (Unit Trust Managers) Limited
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
4. Full name of shareholder(s) (if different from 3.)^v
Name			Legal & General Assurance Society (LGAS)
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
5. Date on which the threshold was crossed or reached^vi:			19 June 2018
6. Date on which issuer notified (DD/MM/YYYY):			21 June 2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached (LGIM)	0.37%	–		0.37%	31,027,894
Position of previous notification (if applicable) (LGIM)	1.53%	–		1.53%
Resulting situation on the date on which threshold was crossed or reached (UTM)	0.30%	–		0.30%	31,027,894
Position of previous notification (if applicable) (UTM)	1.26%	–		1.26%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
ORD NPV		–		116,000			–		0.37%
SUBTOTAL 8. A		116,000					0.37%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)				x
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General Assurance Society (Direct)	0.06%		0.06%

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General Assurance (Pensions Management) Limited (Direct)	–		–

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management Limited (Indirect)	0.37%		0.37%

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General (Unit Trust Managers) Limited (Indirect)	0.31%		0.31%

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Go ETF Solutions	–		–

10. In case of proxy voting, please identify:
Name of the proxy holder		N/A
The number and % of voting rights held		N/A
The date until which the voting rights will be held		N/A

11. Additional information^xvi
Notification using the total voting rights figure of 31,027,894

Place of completion	Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB
Date of completion	21/06/2018

Director/PDMR Shareholding

21.6.2018

RNS Number : 1926S

Faron Pharmaceuticals Oy

21 June 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

PDMR Dealings and

Person Closely Associated with PDMR Dealings

TURKU – FINLAND, 21 June 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 21 June 2018 it was notified of the following PDMR and persons closely associated dealings.

On 19 June 2018, Mr Matti Manner, the Non-Executive Director of Faron had acquired 15,500 ordinary shares in Faron at a price of 56 pence per ordinary share, and a person closely associated with him had acquired 7,900 ordinary shares in Faron at a price of 56 pence per ordinary share.

On 20 June 2018, Mr Yrjö Wichmann, Chief Financial Officer of Faron had acquired 5,200 ordinary shares in Faron at a price of 67 pence per ordinary share and on 21 June 2018, Dr. Pessi Honkasalo, Corporate Legal Counsel of Faron had acquired 1,500 ordinary shares in Faron at a price of 75 pence per ordinary share.

On 21 June 2018, Dr Matti Karvonen, Medical Director of Faron, had acquired 15,000 ordinary shares in Faron at a price of 56 pence per ordinary share and a person closely associated with him had acquired 31,000 ordinary shares in Faron at a price of 57 pence per ordinary share.

On 21 June 2018, Dr. Markku Jalkanen, Chief Executive Officer of Faron, had acquired 12,000 ordinary shares and a person closely associated with him had acquired 24,000 ordinary shares in Faron at a price of 71 pence per ordinary share. Also on 21 June 2018, Dr. Juho Jalkanen, Chief Development Officer of Faron had acquired 12,000 ordinary shares in Faron at a price of 71 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (“MAR”).

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Matti Manner Susanna Hedenström Yrjö Wichmann Pessi Honkasalo Matti Karvonen Minja Pfeiffer Markku Jalkanen Mehto Saima Kuolinpesä Juho Jalkanen
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities / person closely associated – Non-Executive Director and a person closely associated with him – Chief Financial Officer – Corporate Legal Counsel – Medical Director and a person closely associated with him – Chief Executive Officer and a person closely associated with him – Chief Development Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			56.00 GBPp 56.00 GBPp 67.00 GBPp 75.00 GBPp 56.00 GBPp 57.00 GBPp 71.00 GBPp 71.00 GBPp 71.00 GBPp	15,500 7,900 5,200 1,500 15,000 31,000 12,000 24,000 12,000

d.	Aggregated information – Aggregated Volume – Price	N/A N/A
e.	Date of the transaction	June 19, 2018, June 20, 2018 and June 21, 2018
f.	Place of the transaction	London Stock Exchange, AIM Market

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (“ARDS”). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

END

DSHFKDDPQBKDAAB

Director/PDMR Shareholding

21.6.2018

RNS Number : 1056S

Faron Pharmaceuticals Oy

21 June 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

PDMR Dealing

TURKU – FINLAND, 21 June 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 20 June 2018 it was notified that Dr Frank Armstrong, the Non-Executive Chairman of Faron, had acquired 13,300 ordinary shares in Faron at a price of 75 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (“MAR”).

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Frank Armstrong
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities Non-Executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			75.00 GBPp	13,300

d.	Aggregated information – Aggregated Volume – Price	N/A N/A
e.	Date of the transaction	June 20, 2018
f.	Place of the transaction	London Stock Exchange, AIM Market

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (“ARDS”). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

END

DSHFKDDNABKKFAB

Holding(s) in Company

20.6.2018

TR-1: Standard form for notification of major holdings


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			Faron Pharmaceuticals Oy 7437009H31TO1DC0EB42
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ: Disclosure as per company’s Articles of Association						X
3. Details of person subject to the notification obligation^iv
Name			Legal & General Group Plc (Group) Legal & General Investment Management Limited (LGIM) Legal & General (Unit Trust Managers) Limited
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
4. Full name of shareholder(s) (if different from 3.)^v
Name			Legal & General Assurance Society (LGAS)
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
5. Date on which the threshold was crossed or reached^vi:			15 June 2018
6. Date on which issuer notified (DD/MM/YYYY):			19 June 2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached (LGIM)	1.53%	–		1.53%	31,027,894
Position of previous notification (if applicable) (LGIM)	2.98%	–		2.98%
Resulting situation on the date on which threshold was crossed or reached (UTM)	1.26%	–		1.26%	31,027,894
Position of previous notification (if applicable) (UTM)	2.90%	–		2.90%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
ORD NPV		–		476,000			–		1.53%
SUBTOTAL 8. A		476,000					1.53%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)				x
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General Assurance Society (Direct)	0.27%		0.27%

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General Assurance (Pensions Management) Limited (Direct)	–		–

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management Limited (Indirect)	1.53%		1.53%

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General (Unit Trust Managers) Limited (Indirect)	1.26%		1.26%

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Go ETF Solutions	–		–

10. In case of proxy voting, please identify:
Name of the proxy holder		N/A
The number and % of voting rights held		N/A
The date until which the voting rights will be held		N/A

11. Additional information^xvi
Notification using the total voting rights figure of 31,027,894

Place of completion	Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB
Date of completion	19/06/2018

Holdings in Company

18.6.2018

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			FARON PHARMACEUTICALS OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ:
3. Details of person subject to the notification obligation^iv
Name			CANACCORD GENUITY GROUP INC
City and country of registered office (if applicable)			VANCOUVER, CANADA
4. Full name of shareholder(s) (if different from 3.)^v
Name			DISCRETIONARY CLIENTS
City and country of registered office (if applicable)			As above
5. Date on which the threshold was crossed or reached^vi:			14 JUNE 2018
6. Date on which issuer notified (DD/MM/YYYY):			18 JUNE 2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached	4.7566			4.7566	31,027,894
Position of previous notification (if applicable)	5.2686			5.2686

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)	Number of voting rights^ix		% of voting rights
Class/type of shares ISIN code (if possible)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
FI4000153309	N/A	1,475,875	N/A	4.7566

SUBTOTAL 8. A		1,475,875				4.7566

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi		Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi	Physical or cash settlement^xii			Number of voting rights	% of voting rights



				SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)				X
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Canaccord Genuity Group Inc.	4.7566		4.7566
Canaccord Genuity Wealth Group Holdings Limited	4.7566		4.7566
Canaccord Genuity Wealth Group Holdings (Jersey) Limited	4.7566		4.7566
Hargreave Hale Ltd	4.7566		4.7566

10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information^xvi

Place of completion	BLACKPOOL, ENGLAND
Date of completion	18 JUNE 2018